- Home
- MEI vs RIGL Comparison
MEI vs RIGL Comparison
Compare MEI & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MEI | RIGL |
|---|---|---|
| Founded | 1946 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 581.1M | 564.7M |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MEI | RIGL |
|---|---|---|
| Price | $14.18 | $45.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $9.00 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 525.0K | 284.8K |
| Earning Date | 03-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | 42.94 | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | ★ $908,300,000.00 | $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $34.28 |
| Revenue Growth | 11.24 | ★ 64.15 |
| 52 Week Low | $4.88 | $24.84 |
| 52 Week High | $20.38 | $52.24 |
Technical Indicators
Market Signals| Indicator | MEI | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 44.76 | 66.65 |
| Support Level | $13.50 | $40.05 |
| Resistance Level | $15.55 | $49.10 |
| Average True Range (ATR) | 1.33 | 2.23 |
| MACD | -0.36 | 0.54 |
| Stochastic Oscillator | 30.72 | 85.48 |
Price Performance
Historical ComparisonAbout MEI Methode Electronics Inc.
Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, with the majority of revenue from Europe, the Middle East & Africa (EMEA).
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.